Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › fluorouracil

fluorouracil

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of fluorouracil

138 trials tracked of fluorouracil: 34 in phase 3 or 4 and 19 with published results. The most-cited published study has 1240 citations.

138Trials tracked
34Phase 3 & 4
0Recruiting
19With published results
Phase distribution
Phase 3 34 Phase 2 97 Phase 1 6 Other / NA 1
  1. Phase 3 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Completed · 1,240 cited
  2. Phase 3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Completed · 721 cited
  3. Phase 3 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Completed · 525 cited
  4. Phase 3 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Completed · 520 cited
  5. Phase 3 Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) Completed · 446 cited
  6. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed · 289 cited
Show 44 more trials
  1. Phase 3 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed · 267 cited
  2. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 252 cited
  3. Phase 3 An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread Completed · 74 cited
  4. Phase 3 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients Completed · 58 cited
  5. Phase 3 First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) Completed · 38 cited
  6. Phase 3 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Completed · 24 cited
  7. Phase 3 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Completed · 18 cited
  8. Phase 3 Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) Completed · 16 cited
  9. Phase 3 Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer Completed · 14 cited
  10. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
  11. Phase 3 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions Completed · 6 cited
  12. Phase 3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed · 3 cited
  13. Phase 3 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed · 1 cited
  14. Phase 3 Colorectal Cancer Metastatic Completed
  15. Phase 3 Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Completed
  16. Phase 3 Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer Completed
  17. Phase 3 Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer Completed
  18. Phase 3 A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer Completed
  19. Phase 3 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed
  20. Phase 3 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Completed
  21. Phase 3 First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX Completed
  22. Phase 3 ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer Completed
  23. Phase 3 Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Completed
  24. Phase 3 A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer Completed
  25. Phase 3 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed
  26. Phase 3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer Completed
  27. Phase 3 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed
  28. Phase 3 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed
  29. Phase 2 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Completed
  30. Phase 2 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Completed
  31. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  32. Phase 2 Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed
  33. Phase 2 Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer Completed
  34. Phase 2 Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer Completed
  35. Phase 2 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed
  36. Phase 2 Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer Completed
  37. Phase 2 Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma Completed
  38. Phase 2 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction Completed
  39. Phase 2 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
  40. Phase 2 Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor Completed
  41. Phase 2 Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery Completed
  42. Phase 2 A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) Completed
  43. Phase 2 Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) Completed
  44. Phase 2 A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Completed

Showing the 50 most-cited and recently-updated of 138 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Rheumatology Sys. Review
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Frontiers Oct 12, 2026
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer
Oncology Meta-analysis
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer Transcriptomic Signatures May Help Predict Pancreatic Cancer Outcomes
This retrospective pooled analysis of phase 2 trials evaluates transcriptomic signatures and GemPred status in patients with metastatic panc…
New research suggests that specific genetic markers in pancreatic cancer may help predict how well different chemotherapy treatments will wo…
Oct 10, 2026
Pegfilgrastim prophylaxis reduces febrile neutropenia in esophageal cancer patients receiving DCF chemotherapy
ENT (Otolaryngology) Meta-analysis
Pegfilgrastim prophylaxis reduces febrile neutropenia in esophageal cancer patients receiving DCF chemotherapy Pegfilgrastim Reduces Serious Risks for Patients with Esophageal Cancer
This meta-analysis examines prophylactic pegfilgrastim in patients with esophageal cancer receiving docetaxel, cisplatin, and fluorouracil (…
Adding pegfilgrastim to chemotherapy for esophageal cancer can significantly lower the risk of dangerous infections and severe neutropenia.
Oct 8, 2026
Paclitaxel and Cisplatin Combination Improves Outcomes in Locoregionally Advanced Nasopharyngeal Carcinoma
Oncology RCT
Paclitaxel and Cisplatin Combination Improves Outcomes in Locoregionally Advanced Nasopharyngeal Carcinoma Trial shows TPC chemotherapy improves survival for nasopharyngeal carcinoma
A randomized trial demonstrates that TPC induction chemotherapy significantly improves failure-free survival for patients with high-risk nas…
A new clinical trial found that a specific three-drug induction chemotherapy may improve survival rates for patients with high-risk nasophar…
NEJM Evid Aug 27, 2026
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
ENT (Otolaryngology) Meta-analysis
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
May 5, 2026
5-Fluorouracil and MAL-PDT vs Surgery for Bowen's Disease: 4-Year Outcomes
Dermatology RCT
5-Fluorouracil and MAL-PDT vs Surgery for Bowen's Disease: 4-Year Outcomes Surgery kept skin cancer away better than two light-based treatments in this trial
This multicenter RCT compared 5-fluorouracil, methylaminolevulinate photodynamic therapy (MAL-PDT), and surgical excision (SE) in 250 patien…
Surgery offered the highest chance of staying cancer-free for four years, while light-based treatments showed lower success rates in this st…
May 1, 2026
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Oncology RCT
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Apr 28, 2026
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort
Oncology Cohort
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort Most patients on strong pancreatic cancer chemo needed a dose change
This cohort study included 514 patients with pancreatic ductal adenocarcinoma treated at UCSF oncology clinics.
Over 60% of patients with pancreatic cancer needed a dose adjustment during treatment with FOLFIRINOX at UCSF clinics.
medRxiv Apr 28, 2026
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients
Oncology RCT
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients Surgery Doesn’t Extend Life for Advanced Colon Cancer
This randomized clinical trial enrolled 382 adult patients with multiorgan metastatic colorectal cancer across 27 hospitals in the Netherlan…
This large study shows that removing tumors in advanced colon cancer doesn’t help people live longer.
JAMA Apr 23, 2026
Case report details long-term survival in appendiceal signet-ring cell carcinoma with uterine involvement
Oncology Sys. Review
Case report details long-term survival in appendiceal signet-ring cell carcinoma with uterine involvement A rare cancer found in the uterus and ovaries may be treated with surgery and chemo for over five years
This case report describes a 45-year-old woman with signet-ring cell carcinoma of the appendix involving the uterus and ovaries.
A rare cancer starting in the appendix showed up in the uterus and ovaries. Treatment with surgery and drugs helped a woman survive past fiv…
Frontiers Apr 23, 2026
Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer
Geriatrics & Aging Phase II
Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer New Drug Combo Helps Older Pancreatic Cancer Patients Live Longer
This Phase II multicentric study evaluated adapted-dose FOLFIRINOX in 72 elderly patients (aged 70 years or older) with metastatic pancreati…
A new drug mix helps older pancreatic cancer patients live longer while keeping them active, provided doctors check specific genes first to …
CT.gov Apr 16, 2026
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases
Allergy & Immunology Cohort
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases Rare Stomach Cancer Shrinks After New Combo Treatment
This case report and literature review describes a 67-year-old man with AFP-producing gastric adenocarcinoma and liver metastases treated wi…
A rare stomach cancer that spread to the liver shrank dramatically when doctors combined standard chemotherapy with a newer immune-boosting …
Frontiers Apr 16, 2026

All fluorouracil Articles